NCT04535882Completed
Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD
Association Between Serum Leucine-rich Alpha-2 Glycoprotein Levels and Endoscopic Activity of Possible Ulcerative Colitis or Crohn's Disease Colitis
Source: ClinicalTrials.gov · Last updated 7 Aug 2026
Brief summary (registry, in English)
We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (LRG) levels and endoscopic activity in patients with possible ulcerative colitis (UC) or Crohn's disease (CD) to determine whether LRG was a predicting marker for UC or CD.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 673 (actual)
- First submitted
- 28 Aug 2020
- Start date
- 1 Oct 2020
- Primary completion date
- 31 Jul 2026
- Lead sponsor
- Showa Inan General Hospital
- Diseases
- Crohn's disease, Ulcerative colitis
- NCT number
- NCT04535882
What you commit to
- Study type: Observational
- Participants enrolled: 673
- From 1 Oct 2020 to the primary completion date, 31 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- other autoimmune diseases
- acute or chronic renal failure
- chronic heart diseases
- cancer
- acute or chronic systemic infections
Other
- liver cirrhosis
- ischemic colitis
Who the study is looking for
- Patients whom possible UC or Crohn disease was suspected
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Showa Inan General Hospital Coordinator of this site? Confirm its status | Komagane | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.